S L Haskell

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution

Agnès Girard, D Girard, A. R. English et al. · Antimicrobial Agents and Chemotherapy · 1987 · 321 citations

Immunology, Pharmacotherapy, Antimicrobial Chemotherapy +18

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

Thomas D. Gootz, Richard P. Zaniewski, S L Haskell et al. · Antimicrobial Agents and Chemotherapy · 1996 · 134 citations · Full text

S. Pneumoniae, Antimicrobial Chemotherapy, Antibiotic Resistance +17

Bisulfite or sulfite inhibits growth of Helicobacter pylori

Steven J. Hawrylik, David J. Wasilko, S L Haskell et al. · Journal of Clinical Microbiology · 1994 · 45 citations · Full text

Bisulfite-less Bb, Biochemistry, Microbial Physiology +8

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial

Thomas D. Gootz, Katherine E. Brighty, Marge R. Anderson et al. · Diagnostic Microbiology and Infectious Disease · 1994 · 41 citations

Antimicrobial Drug Discovery, Biochemistry, Antibiotics +9

Structure-activity relationships of 6-(heterocyclyl)-methylene penam sulfones. A new class of .BETA.-lactamase inhibitors.

Yuhpyng L. Chen, Cnm-Wu CHANG, K. HEDBERG et al. · The Journal of Antibiotics · 1987 · 38 citations · Full text